Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2011
Business Overview: Anika develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair based on hyaluronic acid (HA). The company operates in orthobiologics, dermal, ophthalmic, surgical, and veterinary markets. A significant portion of operations involves its Italian subsidiary, Anika S.r.l.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2011 | Six Months Ended June 30, 2011 |
|---|---|---|
| Total Revenue | $16,140,852 | $27,878,531 |
| Net Income | $2,282,641 | $2,607,052 |
| Diluted EPS | $0.17 | $0.19 |
| Product Gross Margin | 57% | 54% |
| Cash and Cash Equivalents | $26,829,029 (as of June 30, 2011) | N/A |
| Total Debt | $12,000,000 | N/A |
| Working Capital | $40,103,733 | N/A |
Note: Working Capital calculated as Total Current Assets ($57,485,437) minus Total Current Liabilities ($17,381,704).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 11.3% for the quarter and 3.4% for the six-month period compared to the same periods in 2010. Product revenue rose 12.3% (quarter) and 4.4% (six months).
- Profitability Surge: Net income increased 114.0% for the quarter and 46.4% for the six-month period. Income from operations jumped 103.9% (quarter) and 42.0% (six months).
- Expense Reduction: Operating expenses decreased 1.8% (quarter) and 1.4% (six months) year-over-year, driven by a 14.3% drop in R&D and a 14.8% drop in SG&A expenses.
- Cash Flow: Net cash used in operating activities was $(110,499) for the six months ended June 30, 2011, a reversal from the $779,339 provided by operations in the prior year period. This was due to increased working capital requirements.
- Product Mix Shifts:
- Orthobiologics: Increased 26.8% (quarter) and 21.7% (six months), driven by ORTHOVISC and MONOVISC sales.
- Ophthalmic: Decreased 9.4% (quarter) and 35.9% (six months) due to reduced sales to Bausch & Lomb as they transition suppliers.
- Dermal: Decreased 33.2% (quarter) and 33.4% (six months) following the bankruptcy of former distributor Coapt.
Guidance, Outlook, Risks, and Unusual Items
- Manufacturing Delays: An equipment problem in March 2011 at the Woburn, MA facility delayed shipments of approximately $1.4 million of ophthalmic and ORTHOVISC products into Q2. While shipments resumed in June, backorders for ORTHOVISC remain. FDA approval for the new Bedford, MA facility for aseptic products is now expected in early 2012, delaying the transition of manufacturing.
- Strategic Contracts: The supply agreement with Bausch & Lomb (B&L) for AMVISC products is a two-year transition contract ending in 2012. Revenue from B&L is expected to be significantly lower in 2011 compared to 2010. The company expects overall ophthalmic revenue to decline significantly in 2011.
- Legal Proceedings:
- Genzyme Litigation: Genzyme alleges patent infringement regarding MONOVISC. Anika denies liability and has not accrued for losses, deeming them not probable.
- Artes Bankruptcy: Anika settled a claim from the trustee of former distributor Artes Medical for $30,000 (accrued in June 2011) regarding alleged preferential payments.
- Outlook: Management expects joint health product revenue to increase in 2011. However, gross margins in the U.S. are expected to remain low in 2011 due to the transition of operations and the loss of a product batch in Q1. Future R&D spending is expected to increase modestly for clinical trials (Cingal, Hyalograft C).
Investor Verification Checklist
- MONOVISC FDA Status: Verify the timeline for the Advisory Panel review and potential approval, as this is critical for U.S. revenue growth in the orthobiologics segment.
- Bedford Facility Timeline: Confirm the schedule for FDA licensure of the Bedford, MA facility, as delays impact manufacturing costs and the ability to fulfill backorders.
- Bausch & Lomb Transition: Monitor the decline in ophthalmic revenue as B&L completes its transition to a new supplier and assess the ramp-up of the new AnikaVisc product.
- Genzyme Litigation: Track developments in the patent infringement lawsuit, as an adverse ruling could block U.S. sales of MONOVISC.
- Italian Receivables: Review the collection status of accounts receivable from Italian public hospitals (approx. $2.5 million), which historically have variable payment timing.